William A. Haseltine: Covid Vaccine Trials Are Designed Not to Fail

Health Politics U.S.

William Haseltine says the protocols big pharmaceutical companies are following in their vaccine trials are not nearly rigorous enough. In fact, he says, they are designed to succeed.

Haseltine writes:

“Prevention of infection must be a critical endpoint. Any vaccine trial should include regular antigen testing every three days to test contagiousness to pick up early signs of infection and PCR testing once a week to confirm infection by SARS-CoV-2 test the ability of the vaccines to stave off infection. Prevention of infection is not a criterion for success for any of these vaccines. In fact, their endpoints all require confirmed infections and all those they will include in the analysis for success,  the only difference being the severity of symptoms between the vaccinated and unvaccinated. Measuring differences amongst only those infected by SARS-CoV-2 underscores the implicit conclusion that the vaccines are not expected to prevent infection, only modify symptoms of those infected.”

“We all expect an effective vaccine to prevent serious illness if infected. Three of the vaccine protocols—Moderna, Pfizer, and AstraZeneca—do not require that their vaccine prevent serious disease only that they prevent moderate symptoms which may be as mild as cough, or headache….”

“These vaccine trials are testing to prevent common cold symptoms.” 

We reported just yesterday that Pfizer has manufactured “hundreds of thousands of doses” of its Covid19 vaccine already at its plant in Puurs, Belgium. They are being stockpiled, ready to be rolled out worldwide, if clinical trials are a “success” and “final approval” is reached.

You can read William Hesltine’s assessment of the current vaccine protocols in its entirety here.

Photo by Markus Winkler via Pixabay

Join the discussion